EUROPE AND JAPAN ALLERGY IMMUNOTHERAPY MARKET ANALYSIS

Europe and Japan Allergy Immunotherapy Market, by Treatment (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergy Rhinitis, Allergy Asthma, Pollen Allergies {Cedar, Birch, Oak and Others}, Pet Allergy {Cats, Dogs and Other Pets}, Birds Allergy and Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (Europe and Japan) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022
Code : CMI5037
Pages :508
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Europe: U.K, Germany, Italy, France, Spain, Denmark, Sweden, Poland, Belgium, Netherlands, Russia, Rest of Europe
Japan

Regional Analysis: Among regions, Europe allergy immunotherapy market is expected to hold a dominant position during the forecast period, owing to increasing marketing authorization by the regulatory authorities. For instance, in June 2019, ALK-Abelló A/S announced that it successfully completed the marketing authorization procedure for its tree sublingual allergy immunotherapy (SLIT) tablet in 17 European countries. ITULAZAX is expected to be the brand name of the tree SLIT-tablet.

Europe And Japan Allergy Immunotherapy Market Report Snapshots